Gross Profit Trends Compared: Teva Pharmaceutical Industries Limited vs Viatris Inc.

Teva vs. Viatris: A Decade of Gross Profit Trends

__timestampTeva Pharmaceutical Industries LimitedViatris Inc.
Wednesday, January 1, 2014110560000003669400000
Thursday, January 1, 2015113560000004382200000
Friday, January 1, 2016118590000004998500000
Sunday, January 1, 2017108250000004976200000
Monday, January 1, 201882960000004572000000
Tuesday, January 1, 201975360000004444200000
Wednesday, January 1, 202077250000003796700000
Friday, January 1, 202175940000005575500000
Saturday, January 1, 202269730000006497000000
Sunday, January 1, 202376460000006438600000
Monday, January 1, 20248064000000
Loading chart...

Unleashing insights

Gross Profit Trends: Teva vs. Viatris

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Teva Pharmaceutical Industries Limited and Viatris Inc. from 2014 to 2023. Teva, a global leader in generic medicines, saw its gross profit peak in 2016, followed by a decline of approximately 41% by 2022. Meanwhile, Viatris, formed in 2020 through the merger of Mylan and Upjohn, demonstrated a steady growth, with a notable 77% increase in gross profit from 2014 to 2023.

Key Insights

  • Teva's Decline: Teva's gross profit dropped significantly post-2016, reflecting challenges in the generic drug market and legal issues.
  • Viatris' Growth: Despite being a newer entity, Viatris has shown resilience, with its gross profit surpassing Teva's by 2022.

These trends highlight the dynamic nature of the pharmaceutical sector and the importance of strategic adaptation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025